<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">␣B-Crystallin immunolocalization yields new insights into inclusion body myositis</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Brenda</forename><forename type="middle">L</forename><surname>Banwell</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Andrew</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="laboratory">Neuromuscular Research Laboratory</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<settlement>Rochester</settlement>
									<region>MN</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">Dr. Banwell&apos;s current address is Department of Pediatric Neurology</orgName>
								<orgName type="institution">Hospital for Sick Children</orgName>
								<address>
									<settlement>Toronto</settlement>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>200 First Street SW</addrLine>
									<postCode>55905</postCode>
									<settlement>Rochester</settlement>
									<region>MN</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">␣B-Crystallin immunolocalization yields new insights into inclusion body myositis</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">CFC8CB135DF1680A270097E6ACA933C4</idno>
					<note type="submission">Received September 8, 1999. Accepted in final form November 19, 1999.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2023-03-30T18:13+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>␣B-crystallin-Inclusion body myositis-Immunolocalization-T-cell response-Myopathies</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>To study the expression of the small heat shock protein, ␣B-crystallin (␣BC), in inclusion body myositis (IBM). Background: In humans, ␣BC is constitutively expressed in the eye lens, muscle, and heart, but not in lymphoid tissues. Induced expression of ␣BC occurs under metabolic stress, in virus-infected lymphocytes, and in degenerative brain lesions, including neurofibrillary tangles and senile plaques in AD. The previously reported pathologic similarities between AD and IBM prompted us to study ␣BC expression in IBM. Methods: Immunolocalization of ␣BC in muscle of 11 patients with IBM, 50 patients with other muscle diseases, and 4 controls; and quantitative analysis of the frequency of fibers with 1) increased ␣BC expression in IBM and polymyositis and 2) structural abnormality (vacuolated, non-necrotic and invaded by mononuclear cells, Congo red-positive, SMI-31 positive, and ubiquitin positive) in IBM. Results: We detected enhanced expression of ␣BC not only in all structurally abnormal IBM fibers, but also, and with severalfold higher frequency, in IBM fibers without significant structural abnormality (X fibers) ( p values in paired t-tests Ͻ 0.001). We also found enhanced ␣BC in abnormal fibers in other diseases; X fibers, however, were extremely sparse or absent, except in two atypical cases of polymyositis refractory to immunotherapy. Conclusion: That the X fibers are much more frequent than the structurally abnormal fibers in IBM points to a pathogenic stressor acting upstream to the development of structural abnormalities. The identification of this stressor is now of paramount importance for deciphering the enigma of IBM.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>The ␣-crystallins are members of the small heat shock protein (Hsp) family that also includes Hsp 20 and Hsp 27. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref> The A and B forms of ␣-crystallin, encoded by different genes, are abundant in the eye lens, where they form large multimeric complexes that prevent cataract formation. <ref type="bibr" target="#b0">1</ref> ␣B-Crystallin (␣BC) is also expressed in other tissues, <ref type="bibr" target="#b2">3</ref> where it is known to chaperone for actin and desmin filaments, <ref type="bibr" target="#b3">4</ref> tubulin subunits of microtubules, <ref type="bibr" target="#b4">5</ref> and a variety of soluble enzymes, <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7</ref> protecting them from stressinduced damage. <ref type="bibr" target="#b7">8</ref> Unlike some other heat shock proteins, ␣BC is not constitutively expressed in all tissues. It is present in high concentration in cardiac and skeletal muscle, <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref> where it associates with actin and desmin at the Z-disc. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b9">10</ref> It is expressed at a low level in glial cells in brain, renal epithelial cells, and lung. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b11">12</ref> Unlike in other mammalian species, in humans, ␣BC is not normally detected in lymphoid tissues, <ref type="bibr" target="#b12">13</ref> but its expression in B cells can be induced by viral infections. <ref type="bibr" target="#b12">13</ref> Consistent with its role as a heat shock protein, ␣BC expression is increased by thermal or osmotic stress. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b13">14</ref> In humans, accumulation of ␣BC occurs in glial cytoplasmic inclusions in multiple system atrophy, <ref type="bibr" target="#b14">15</ref> ballooned neurons in frontotemporal dementia, <ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b16">17</ref> degenerating neurons in progressive supranuclear palsy, <ref type="bibr" target="#b17">18</ref> cortical Lewy bodies, <ref type="bibr" target="#b11">12</ref> astrocytic Rosenthal fibers in Alexander's disease, <ref type="bibr" target="#b11">12</ref> oligodendrocytes in areas of active demyelination in MS, <ref type="bibr" target="#b12">13</ref> and reactive astrocytes and microglia found in or near senile plaques and neurofibrillary tangles in AD. <ref type="bibr" target="#b18">19</ref> The histologic hallmarks of inclusion body myositis (IBM) include the appearance in vacuolated muscle fibers of congophilic inclusions that also bind SMI-31 (an antibody directed against phosphorylated neurofilaments), and abnormal expression in these fibers of ␤-amyloid protein, ␤-amyloid precursor protein, and ubiquitin. <ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b20">21</ref> The vacuolated fibers also express a variety of other proteins normally expressed only at the neuromuscular junction, and in lesions in AD. <ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b20">21</ref> These findings have led to the hypothesis that abnormalities in muscle in IBM are akin to those found in brain in AD. <ref type="bibr" target="#b20">21</ref> The increased expression of ␣BC in reactive astrocytes and micro-glia near senile plaques and neurofibrillary tangles in AD prompted us to immunolocalize ␣BC in muscle fibers in IBM.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods.</head><p>Patients. Limb muscle specimens were obtained from 11 patients with IBM, 50 patients with other muscle diseases, and 4 nonweak controls. Table <ref type="table" target="#tab_0">1</ref> lists the diagnoses and clinical features of the patients. The diagnoses were based on the clinical examination, family history, EMG, and muscle biopsy studies, which, when appropriate, included immunostains for dystrophin, adhalin, merosin, emerin, desmin, gelsolin, neural cell adhesion molecule (NCAM), ␣1-antichymotrypsin, and /m calpain. The histologic criteria for the diagnosis of IBM included fibers harboring rimmed vacuoles, an autoaggressive inflammatory exudate, congophilic and SMI-31-positive inclusions, small or large groups of atrophic fibers, and mitochondrial alterations consisting of ragged-red, raggedblue, and cytochrome c oxidase-negative fibers. <ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref> The histologic criteria for the diagnosis of polymyositis included an autoaggressive inflammatory exudate and absence of rimmed vacuoles or congophilic inclusions. <ref type="bibr" target="#b25">26</ref> The histologic criteria for the diagnosis of myofibrillar myopathy included fibers harboring large hyaline structures and lakes of amorphous material; ectopic expression of desmin, gelsolin, ␣1-antichymotrypsin, and NCAM; and the presence of large congophilic deposits in the muscle fibers. <ref type="bibr" target="#b26">27</ref> Histologically normal muscle specimens from patients without muscle disease were used as controls. All human studies were in accord with the guidelines of the Institutional Review Board of the Mayo Clinic.</p><p>Histochemical and immunocytochemical studies. Flashfrozen muscle specimens were stored under liquid nitrogen until use. For conventional histochemical studies, 10-m frozen sections were stained or reacted for hematoxylin and eosin, modified Gomori trichrome, NADH dehydroge-nase, ATPase (after preincubation at pH 4.3, 4.5, and 9.4), acid phosphatase, nonspecific esterase, periodic acid-Schiff (PAS), oil red O, and Congo red. <ref type="bibr" target="#b27">28</ref> For immunocytochemical studies, 6-m frozen sections were immunostained with the primary antibodies listed in table <ref type="table" target="#tab_1">2</ref>. Nonspecific binding was blocked by preincubation in phosphate-buffered saline, pH 7.4, containing 2% bovine serum albumin and 5% donkey serum or 10% goat serum. The primary antibodies and the corresponding nonimmune immunoglobulin G (IgG) controls were diluted in the blocking solution. Mouse monoclonal antibodies directed against ␣BC, Hsp 65, Hsp 27, and neuronal (nNOS) and inducible nitric oxide synthase (iNOS) were localized with the immunoperoxidase method using a biotinylated goat antimouse second antibody and the ABC kit (Vector Laboratories, Burlingame, CA). Ubiquitin, SMI-31, desmin, ␣1antichymotrypsin, and actin were visualized by immunofluorescence with detection of the first antibody by a CY3labeled second antibody, or using a biotinylated second antibody followed by fluorescein isothiocyanate (FITC)labeled streptavidin. Two-color immunofluorescence studies were done to colocalize ␣BC, detected with a polyclonal rabbit antibody, and desmin, ␣1-antichymotrypsin, and actin, detected with mouse monoclonal antibodies. Controls consisted of replacement of monoclonal antibodies with nonimmune IgG of the same subclass and concentration as the primary antibody, or replacement of polyclonal antibodies with appropriately diluted nonimmune serum. All secondary antibodies were multilabel grade, applied at 5 g/mL, and were from Jackson Immunoresearch (West Grove, PA).</p><p>All muscle specimens were immunostained for ␣BC. IBM muscle specimens were immunostained for each antibody listed in table 2. Ubiquitin and SMI-31 were immunolocalized in all polymyositis cases. All muscular dystrophy specimens had been previously immunostained for dystro- phin; laminin-␣-2; ␣, ␤, ␥, and ␦-sarcoglycan; and ␤-dystroglycan. The expression of ␣1-antichymotrypsin, actin, NCAM, and dystrophin was studied in all cases of myofibrillar myopathy.</p><p>To correlate the ␣BC positivity with structural changes in the muscle fiber, a section in the series was stained with trichrome. Other sections in the series were reacted for NADH dehydrogenase, ATPase (pH 4.6), or stained with Congo red and viewed under rhodamine optics. <ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b28">29</ref> Quantitative analysis. To evaluate the frequency of ␣BC-positive fibers and of other abnormalities in IBM, all muscle fibers in a trichrome-stained section of each IBM specimen were photographed and counted. A total of 26,863 muscle fibers were surveyed. The following were than counted in serial adjacent or nonadjacent sections: 1) ␣BC-positive fibers; 2) fibers with congophilic inclusions; 3) fibers immunoreactive for SMI-31; and 4) fibers containing ubiquitin-positive deposits. The ␣BC-positive fibers were further classified as follows: i) without significant structural abnormality (we included fibers with a single internal nucleus or a slightly altered intermyofibrillar membranous network in this group); ii) vacuolated; iii) necrotic; iv) regenerating; and v) non-necrotic fibers invaded by mononuclear cells.</p><p>In polymyositis, the number of ␣BC-positive fibers was determined semiquantitatively by counting all muscle fibers and all crystallin-positive muscle fibers in four randomly selected low-power fields in each specimen. Altogether, 4848 fibers were surveyed. The ␣BC-positive fibers were subclassified as described above.</p><p>Results. Species of ␣BC-positive fibers in muscle. In normal muscle, all fibers show faint ␣BC positivity (figure <ref type="figure" target="#fig_0">1O</ref>). ␣BC expression is increased at myomuscular and myotendinous junctions but not at neuromuscular junc-tions. The following patterns of ␣BC expression were observed in biopsy specimens of diseased muscle: 1) fine or coarsely granular deposits, scattered diffusely or aggregated into large clumps, and occupying a variable fraction of the fiber area (see figure <ref type="figure" target="#fig_0">1, A, B, F, and N</ref>, and figure 2D); 2) diffuse deposits, occupying all or part of the entire fiber area (see figure <ref type="figure" target="#fig_0">1D</ref> and figure <ref type="figure">2, E, G, and I</ref>); 3) mottled or diffuse deposits in necrotic (see figure <ref type="figure" target="#fig_0">1M</ref>) and regenerating fibers; 4) subsarcolemmal accumulations (see figures 1M and 2B); 5) increased expression around vacuoles in vacuolated fibers in IBM (see figure <ref type="figure" target="#fig_0">1I</ref>); 6) increased expression in non-necrotic muscle fibers in a mantle-like zone subjacent to invading mononuclear cells (see figure <ref type="figure" target="#fig_0">1K</ref>); and 7) fibers displaying a combination of the above patterns (see figure <ref type="figure" target="#fig_0">1I</ref> and figure <ref type="figure">2, I and K</ref>).</p><p>Inclusion body myositis. Numerous ␣BC-positive muscle fibers were present in all 11 IBM specimens (figure <ref type="figure" target="#fig_0">1,  A, B, I, and K</ref>). The frequency of ␣BC-positive fibers in the individual specimens ranged from 3.2% to 19.8% (figure <ref type="figure">3</ref> and table <ref type="table" target="#tab_2">3</ref>). Examination of the ␣BC-positive fibers in adjacent trichrome sections enabled us to classify them as vacuolated (figure <ref type="figure" target="#fig_0">1, H and I</ref>), necrotic, regenerating, nonnecrotic and invaded by mononuclear cells (figure <ref type="figure" target="#fig_0">1</ref>, H and I), or without significant structural abnormality (figure <ref type="figure" target="#fig_0">1</ref>, C to F; figure <ref type="figure">3</ref>; and table 3). For convenience, from here on ␣BC-positive fibers without significant structural abnormality will be referred to as X fibers. The frequency of the X fibers ranged from 2.6% to 19%, and in each case exceeded the frequency of ubiquitin-, SMI-31-, or Congo red-positive fibers severalfold ( p values based on paired t-tests Ͻ 0.001) (see figure <ref type="figure">3 and table 3</ref>). It was of interest, however, that those specimens with the highest percentage of X fibers also had the highest percentage of fibers harboring SMI-31-, ubiquitin-, or Congo red-positive deposits (see figure <ref type="figure">3</ref>). The SMI-31-positive and  ubiquitin-positive fibers were typically vacuolated and structurally abnormal. Colocalization studies in two IBM specimens showed that all SMI-31-positive fibers and some, but not all, ubiquitin-positive fibers were also ␣BCpositive. We detected no correlation between the duration of symptoms or treatment before biopsy and the frequency of ␣BC-positive fibers in individual patients.</p><p>Because ␣BC associates with desmin and actin, 4,9,10 we colocalized these proteins with ␣BC by two-color immunofluorescence. The X fibers did not show increased immunoreactivity for desmin or actin. ␣BC can form a multiaggregate complex with Hsp 27, another small heat shock protein. <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b13">14</ref> However, Hsp 27 expression was not increased in the X fibers.</p><p>As previously reported, <ref type="bibr" target="#b29">30</ref> the expression of Hsp 65 was enhanced in non-necrotic muscle fibers invaded by mononuclear cells in a mantle-like zone subjacent to the invading cells. This pattern of localization is identical to that observed with ␣BC. Apart from the invaded fibers, and specifically in the X fibers, Hsp 65 expression was not</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 2. ␣B-Crystallin (␣BC) immunolocalizations. (A, B) Polymyositis. Central hypercontracted fiber seen in trichrome (A) and immunostained (B) sections displays subsarcolemmal ␣BC reactivity. (C, D) Polymyositis. Trichrome (C) and immunostained (D) sections; granular ␣BC deposits appear in structurally abnormal fibers. (E, F) Acute quadriplegic myopathy, immunostained (E) and trichrome (F) sections; ␣BC expression is diffusely increased in the numerous small fibers. (G, H) Dermatomyositis. Immunostained (G) and trichrome (H) sections; diffuse and subsarcolemmal increases of ␣BC occur in the abnormal perifascicular fibers. (I-K) Myofibrillar myopathy. Immunostained (I, K) and trichrome (J) sections. In (I), myriad fibers harbor focal increases of ␣BC. In (K), ␣BC deposits outline hyaline structures, highlight segments of the sarcolemma, and appear in other fiber regions. Compare with adjacent trichrome section (J). (A-H) ϫ 170, (I) ϫ 60, (J, K) ϫ 150.</head><p>increased in IBM. The expression of Hsp 70 was increased in invaded, vacuolated, necrotic, and regenerating fibers, but not in X fibers.</p><p>Recently, oxidative stress was proposed to play a role in the pathogenesis of IBM. <ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref> The evidence for this rests on expression of markers of oxidative stress, nNOS, iNOS, and nitrotyrosine, in the vacuolated fibers. <ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b31">32</ref> We confirmed the increased expression of nNos and iNOS in vacuolated fibers in IBM. Numerous nonvacuolated ␣BC-positive fibers, however, expressed neither nNOS nor iNOS.</p><p>Polymyositis. As in IBM, increased ␣BC expression was detected in necrotic and regenerating fibers, nonnecrotic invaded fibers, and fibers without significant structural abnormality (X fibers). In addition, subsarcolemmal ␣BC expression was accentuated in some fibers (figure <ref type="figure">2, C and D</ref>). In 8 out of 10 patients, the frequency of the X fibers ranged from 0.1% to 1.6% (mean 0.78%). By contrast, in two other patients with atypical polymyositis (see Discussion), the frequency of the X fibers was 27% and 4.9%. Most of these fibers harbored granular ␣BC deposits in a pattern similar to that seen in IBM.</p><p>Dermatomyositis. In all five cases of dermatomyositis, ␣BC expression was increased in the abnormal perifascicu-lar fibers, many of which displayed myofibrillar rarefaction, focal basophilia, necrosis, or regeneration (figure <ref type="figure">2, G  and H</ref>).</p><p>Myofibrillar myopathy. Increased ␣BC expression was previously noted in myofibrillar myopathy. <ref type="bibr" target="#b33">34</ref> The recent discovery of a pathogenic mutation in ␣BC in a myofibrillar myopathy kinship <ref type="bibr" target="#b34">35</ref> prompted us to study ␣BC expression in six patients with this disease. None of our patients had cataracts, a feature reported in patients with the ␣BC mutation. <ref type="bibr" target="#b35">36</ref> In all six patients, myriad abnormal muscle fibers reacted intensely for ␣BC (figure <ref type="figure">2</ref>, I to K). In trichrome sections, the abnormal fibers displayed two more or less distinct types of lesions: hyaline structures, and lakes of amorphous material (see figure <ref type="figure">2J</ref>). ␣BC outlined the hyaline structures but was absent or only faintly present in their interior (see figure <ref type="figure">2K</ref>). The nonhyaline lesions reacted intensely for ␣BC (see figure <ref type="figure">2K</ref>). Colocalization studies showed that the majority of ␣BC-positive regions also reacted for desmin and ␣1-antichymotrypsin. ␣BC was not expressed in structurally normal muscle fibers.</p><p>Muscular dystrophies. In four patients with Duchenne dystrophy, five with limb girdle dystrophy (one with attenuated immunoreactivity for members of the sarcoglycan complex), and five with congenital muscular dystrophy (one merosin-negative), hypercontracted fibers showed increased subsarcolemmal ␣BC expression (see figure <ref type="figure" target="#fig_0">1M</ref>). Rarely, structurally intact fibers, or fibers with regions that were unevenly stained by trichrome, displayed punctate increases in ␣BC. These fibers represented Ͻ0.1% of the total in any one specimen, and were absent in some specimens. Lobulated fibers, prominent in one patient with limb girdle dystrophy, displayed subsarcolemmal increases in ␣BC.</p><p>Mitochondrial myopathy. Increased ␣BC expression was noted in relation to the subsarcolemmal mitochondrial accumulations, as previously reported. <ref type="bibr" target="#b36">37</ref> Acute quadriplegic myopathy. Numerous small, basophilic fibers reacted diffusely for ␣BC (figure <ref type="figure">2, E and F</ref>). The pattern of expression resembles that reported with /m calpain in this disease. <ref type="bibr" target="#b22">23</ref> Type 2 fiber atrophy. Studies of disuse atrophy in the rat model show decreased ␣BC expression in atrophic type 2 fibers. <ref type="bibr" target="#b9">10</ref> However, glucocorticoid hormones, which frequently cause type 2 fiber atrophy, increase the expression of ␣BC and its mRNA in cultured cells. <ref type="bibr" target="#b37">38</ref> We therefore studied five patients with type 2 fiber atrophy, three under treatment with prednisone, and two untreated. In one prednisone-treated and one untreated patient, ␣BC expression was prominent in the atrophic type 2 fibers. In the other three patients, the atrophic type 2 fibers were faintly more reactive than type 2 fibers in control muscle. ␣BC expression was not decreased in the atrophic type 2 fibers.</p><p>Denervation atrophy. ␣BC expression was strongly enhanced in the center of target formations (see figure <ref type="figure" target="#fig_0">1N</ref>), but was not increased in single or grouped atrophic fibers.</p><p>Discussion. ␣BC-positive fibers in IBM. Our initial aim was to determine whether ␣BC expression is enhanced in vacuolated muscle fibers in IBM. This was indeed the case, but we also detected enhanced ␣BC expression in many other fibers without signifi-Figure <ref type="figure">3</ref>. Frequency of different types of fibers in 11 cases of inclusion body myositis. For each patient (represented by a number), the frequency of noninvaded, non-necrotic, and nonvacuolated ␣B-crystallin (␣BC)-positive fibers (X fibers) is severalfold higher than that of fibers that display these abnormalities, contain congophilic inclusions, or are immunostained for ubiquitin or SMI-31. Crys ϭ ␣BC; ϩ ϭ positive; SMI-31 ϭ antibody directed against hyperphosphorylated tau protein. cant structural abnormality (X fibers). Moreover, in each of 11 IBM patients, the frequency of X fibers was severalfold higher than the frequency of any other species of abnormal fibers. Because all vacuolated fibers also show enhanced ␣BC positivity, the enhanced ␣BC expression in the X fibers is likely an upstream event in the pathogenesis of IBM. The X fibers do not express Hsp 65, Hsp 70, or Hsp 27. This suggests that the putative stressor specifically stimulates the expression of ␣BC, rather than inciting a nonspecific heat shock/stress response. Increased oxidative stress was proposed as a mediator of muscle damage in IBM, as shown by expression of markers of oxidative stress (nNOS, iNOS, and nitrotyrosine) in vacuolated fibers. <ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b31">32</ref> However, the X fibers express neither nNOS nor iNOS.</p><p>There is experimental evidence that ␣BC expression is enhanced by heat, hypertonic stress, and continuous contractile activity, <ref type="bibr" target="#b38">39</ref> and by glucocorticoids, <ref type="bibr" target="#b37">38</ref> prostaglandins, <ref type="bibr" target="#b39">40</ref> colchicine, <ref type="bibr" target="#b40">41</ref> and vinblastine. <ref type="bibr" target="#b40">41</ref> These factors, however, are not likely to operate continuously in most patients with IBM.</p><p>␣BC expression is also induced by tumor necrosis factor-␣ (TNF␣). <ref type="bibr" target="#b13">14</ref> TNF␣-responsive genes are regulated by the nuclear transcription factor B (NF-B). <ref type="bibr" target="#b13">14</ref> The 5Ј end of the gene encoding ␣BC contains a consensus sequence for NF-B, <ref type="bibr" target="#b13">14</ref> and ␣BC has been shown to protect cultured cells against TNF␣induced cell death. <ref type="bibr" target="#b41">42</ref> Increased expression of NF-B was reported in necrotic and vacuolated fibers in IBM, <ref type="bibr" target="#b42">43</ref> and variably increased levels of TNF␣ mRNA were detected in IBM muscle specimens. <ref type="bibr" target="#b43">44</ref> However, increased expression of NF-B was not observed in nonvacuolated fibers in IBM <ref type="bibr" target="#b42">43</ref> ; hence, the increased expression of ␣BC in the X fibers cannot be directly correlated with enhanced expression of NF-B.</p><p>The ultrastructural localization of ␣BC in X fibers, and particularly in fibers that just start to overexpress ␣BC, might yield insights into the functional role of ␣BC in IBM. ␣BC, however, is a soluble protein; therefore, its ultrastructural localization in fixed muscle fibers may not yield reliable information as to what organelles it associates with in the native state.</p><p>Muscle fibers in IBM were previously shown to express a protein that binds single-stranded DNA. Most of the sites of binding were nuclear, but some were rimmed vacuoles. <ref type="bibr" target="#b44">45</ref> The identity of this protein is not known, but it is unlikely to be ␣BC, for ␣BC expression in IBM is not selectively enhanced in relation to nuclei and is also observed in numerous nonvacuolated fibers.</p><p>Could ␣BC act as an autoantigen in IBM? ␣BC can exist in differentially phosphorylated forms, <ref type="bibr" target="#b45">46</ref> the degree of phosphorylation depending on stress and on tissue-or age-related factors. <ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref> In mice, stress-induced phosphorylation of ␣BC creates epitopes recognized by T cells in the context of major histocompatibility complex (MHC) class II molecules. <ref type="bibr" target="#b48">49</ref> Based on studies showing that ␣BC-positive myelin acts as an immunodominant autoantigen to human T cells, <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b48">49,</ref><ref type="bibr" target="#b49">50</ref> ␣BC has been proposed as a candidate autoantigen in MS. <ref type="bibr" target="#b49">50</ref> Human lymphocytes do not constitutively express ␣BC and are not tolerized to it. Infection of human peripheral blood B cells with Epstein-Barr virus induces ␣BC expression and results in MHC class II-restricted presentation of ␣BC epitopes to T cells. <ref type="bibr" target="#b12">13</ref> On this basis, it has been hypothesized that the resulting T cell response is cross reactive with CNS myelin, and could contribute to the development of MS. <ref type="bibr" target="#b12">13</ref> Although this hypothesis is yet to be confirmed, it raises some intriguing questions: 1) Could a modified form of ␣BC, expressed in muscle, instigate the autoaggressive T cell response in IBM? Consistent with this notion is that fragments of heat shock proteins are among the naturally processed peptides associated with MHC class I molecules on the cell surface. <ref type="bibr" target="#b50">51</ref> 2) We detected X fibers in sporadic IBM; are X fibers also present in hereditary inclusion body myopathy where there is no T-cell response in muscle? Preliminary studies by Sadeh and Argov show that the X fibers are not present in hereditary inclusion body myopathy (personal communication, 1999). 3) If ␣BC instigates a T-cell response in sporadic IBM, then why does the increased expression of ␣BC by numerous degenerating fibers in myofibrillar myopathy not have a similar effect? Possible reasons for this could be that ␣BC accumulating in X fibers in sporadic IBM is structurally different from ␣BC expressed by degenerating fibers in myofibrillar myopathy, or that the cytokine milieu in muscle in the two diseases is different.</p><p>␣BC-positive fibers in polymyositis. Increased ␣BC expression in structurally intact fibers (X fibers) is not specific for IBM. In 8 out of 10 polymyositis patients, X fibers were present, but at a much lower frequency, than in IBM. In two patients, however, these fibers were as frequent as in IBM. Although the histologic hallmarks of IBM were absent in these two patients, both were refractory to immunosuppressants and had selectively severe quadriceps weakness. The diagnosis of IBM was suspected, but both declined a second muscle biopsy.</p><p>␣BC-positive fibers in other disorders. The increased ␣BC expression in structurally abnormal fibers in myofibrillar myopathy, in myosin-depleted fibers in acute quadriplegic myopathy, and in target formations may be in response to disruption of the myofibrillar architecture. Such a response is consistent with the chaperone role of ␣BC for actin and desmin as well as other proteins, <ref type="bibr" target="#b51">52</ref> and with the rapid activation of heat shock protein genes by misfolded proteins in tissue culture models. <ref type="bibr" target="#b52">53</ref> The inciting events leading to increased ␣BC expression in necrotic and regenerating fibers and in the perifascicular degenerating fibers in dermatomyositis are probably varied. Necrotic fibers have undergone marked myofibrillar alterations, regenerating fibers are actively engaged in protein synthesis and folding, and the perifascicular fibers in dermatomyositis are likely metabolically "stressed" by ischemia or other factors. <ref type="bibr" target="#b25">26</ref> Possible causes and consequences of ␣BC expression in X fibers. The lack of significant structural alteration in the X fibers implies that the increased ␣BC expression in these fibers is an early event in the course of muscle fiber injury. In that case, one can assume that the accumulation of ␣BC is triggered by a yet unidentified stressor, and that the enhanced expression of ␣BC is to protect the muscle fiber from degeneration. It also follows that the unidentified stressor acts on a much larger number of fibers than those that are vacuolated, necrotic, or invaded by mononuclear cells. By analogy to the induced expression of ␣BC in lymphocytes by viral infections, <ref type="bibr" target="#b12">13</ref> one could speculate that the unidentified stressor represents a viral infection. A search for genomes of mumps virus, <ref type="bibr" target="#b53">54,</ref><ref type="bibr" target="#b54">55</ref> enterovirus, <ref type="bibr" target="#b55">56</ref> coxsackie virus, <ref type="bibr" target="#b56">57</ref> adenovirus, <ref type="bibr" target="#b57">58</ref> human T-lymphotropic virus (HTLV) types I and II, <ref type="bibr" target="#b57">58</ref> HIV, <ref type="bibr" target="#b57">58</ref> and encephalomyocarditis virus <ref type="bibr" target="#b57">58</ref> was negative in IBM. The HTLV-1 antigen was observed by immunostain in one IBM muscle specimen, <ref type="bibr" target="#b58">59</ref> but this was not confirmed. <ref type="bibr" target="#b59">60</ref> Not all viral genomes, however, have been searched for in IBM to date. Moreover, the continued presence of a triggering infectious agent may not be required for disease progression. <ref type="bibr" target="#b60">61</ref> </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc>Figure 1. ␣B-Crystallin (␣BC) immunolocalizations. (A-K) Inclusion body myositis. Granular ␣BC deposits appear in numerous fibers in (A) and (B); two of these are vacuolated in (A). Two fibers with markedly enhanced ␣BC expression (D, F) show no significant abnormality in adjacent trichrome sections (C, E). Vacuolated fibers, seen in trichrome (H) and immunostained (I) sections, display granular and perivacuolar ␣BC deposits. Non-necrotic muscle fiber focally surrounded and invaded by mononuclear cells, seen in trichrome (J) and immunostained (K) sections, shows a mantle of ␣BC subjacent to the invading cells. (L, M) Limb-girdle dystrophy. Two necrotic and a hypercontracted fiber are present in trichrome (L) and immunostained (M) sections. The necrotic fibers show faint, mottled ␣BC deposits; the hypercontracted fiber is outlined by intense subsarcolemmal ␣BC reactivity. (N) Intense ␣BC expression in the center of target formations. (O) Faint ␣BC reactivity in normal muscle. (A) ϫ 180, (B) ϫ 225, (C-O) ϫ 185.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc>Clinical features</figDesc><table><row><cell>Diagnosis</cell><cell>No. of cases</cell><cell>Sex, M/F</cell><cell>Mean age, y (range)</cell><cell>Creatine kinase U/L (range)*</cell></row><row><cell>Inclusion body myositis †</cell><cell>11</cell><cell>9/2</cell><cell>66 (50-81)</cell><cell>507 (165-1225)</cell></row><row><cell>Polymyositis ‡</cell><cell>10</cell><cell>2/8</cell><cell>62 (49-81)</cell><cell>967 (127-5360)</cell></row><row><cell>Dermatomyositis</cell><cell>5</cell><cell>3/2</cell><cell>58 (29-78)</cell><cell>186 (61-391)</cell></row><row><cell>Duchenne dystrophy</cell><cell>4</cell><cell>3/1 §</cell><cell>2.4 (0.8-4)</cell><cell>23,941 (10,360-36,000)</cell></row><row><cell>Congenital muscular dystrophy</cell><cell>5</cell><cell>2/3</cell><cell>1.8 (0.16-3)</cell><cell>1192 (614-2150)</cell></row><row><cell>Limb girdle dystrophy</cell><cell>5</cell><cell>0/5</cell><cell>32 (15-43)</cell><cell>7536 (74-31,104)</cell></row><row><cell>Myofibrillar myopathy</cell><cell>6</cell><cell>3/3</cell><cell>54 (21-71)</cell><cell>456 (198-960)</cell></row><row><cell>Mitochondrial myopathy</cell><cell>5</cell><cell>1/4</cell><cell>39 (24-49)</cell><cell>757 (100-1942)</cell></row><row><cell>Acute quadriplegic myopathy</cell><cell>3</cell><cell>1/2</cell><cell>59 (58-70)</cell><cell>107 (18-220)</cell></row><row><cell>Type 2 fiber atrophy</cell><cell>5</cell><cell>3/2</cell><cell>62 (52-71)</cell><cell>101 (28-200)</cell></row><row><cell>Denervation atrophy</cell><cell>2</cell><cell>2/0</cell><cell>68 (66-69)</cell><cell>576 (200-952)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc>Primary antibodies</figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Concentration/</cell></row><row><cell>Antigen</cell><cell>Immunogen</cell><cell>Antibody</cell><cell>Clone</cell><cell>Source</cell><cell>dilution</cell></row><row><cell>␣B-Crystallin</cell><cell>Bovine eye lens</cell><cell>Mouse MAB</cell><cell cols="2">1B6.1-3G4 StressGen</cell><cell>1/1000</cell></row><row><cell>␣B-Crystallin</cell><cell>Human ␣B-crystallin, residues 1-10</cell><cell>Rabbit PAB</cell><cell></cell><cell>Novocastra</cell><cell>1/400-1/600</cell></row><row><cell>SMI-31</cell><cell>Phosphorylated neurofilament</cell><cell>Mouse MAB</cell><cell></cell><cell>Sternberger</cell><cell>1/1000</cell></row><row><cell></cell><cell>heavy chain</cell><cell></cell><cell></cell><cell>Monoclonal</cell><cell></cell></row><row><cell>Ubiquitin</cell><cell>Purified bovine red blood cells</cell><cell>Mouse MAB</cell><cell></cell><cell>Chemicon</cell><cell>1/50</cell></row><row><cell>Hsp 70</cell><cell>Human Hsp 70</cell><cell>Mouse MAB</cell><cell>5A5</cell><cell>Affinity</cell><cell>1/100</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Bioreagents</cell><cell></cell></row><row><cell>Hsp 65</cell><cell>M. leprae Hsp 65</cell><cell>Mouse MAB</cell><cell>ML-30</cell><cell>J. Ivanyi</cell><cell>1/100</cell></row><row><cell>Hsp 27</cell><cell>Prokaryote Hsp 27</cell><cell>Mouse MAB</cell><cell></cell><cell>Novocastra</cell><cell>1/40-1/100</cell></row><row><cell>Neuronal nitric oxide synthase</cell><cell>Human nNOS</cell><cell>Rabbit PAB</cell><cell>16</cell><cell>Transduction</cell><cell>1/100</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Laboratories</cell><cell></cell></row><row><cell>Inducible nitric oxide synthase</cell><cell>Mouse iNOS</cell><cell>Rabbit PAB</cell><cell>6</cell><cell>Transduction</cell><cell>1/200</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Laboratories</cell><cell></cell></row><row><cell>Desmin</cell><cell>Whole human desmin</cell><cell>Mouse MAB</cell><cell>D33</cell><cell>Dako</cell><cell>1/400</cell></row><row><cell>␣1-Antichymotrypsin</cell><cell>␣1-Antichymotrypsin</cell><cell>Mouse MAB</cell><cell>8E6</cell><cell>Biodesign</cell><cell>1/500</cell></row><row><cell>Actin</cell><cell>Human myocardium</cell><cell>Mouse MAB</cell><cell>HHF35</cell><cell>Dako</cell><cell>0.2 g/mL</cell></row></table><note>MAB ϭ monoclonal antibody; PAB ϭ polyclonal antibody; Hsp ϭ heat shock protein.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc>Percentage of abnormal fibers in inclusion body myositis</figDesc><table><row><cell>Characteristic</cell><cell>Mean Ϯ SE (range)</cell></row><row><cell>All ␣B-crystallin positive</cell><cell>9.8 Ϯ 1.6 (3.2-19.8)</cell></row><row><cell>␣B-Crystallin positive, nonnecrotic,</cell><cell>8.5 Ϯ 1.5 (2.6-19.1)</cell></row><row><cell>nonvacuolated, noninvaded (X fibers)</cell><cell></cell></row><row><cell>Congo red positive</cell><cell>0.73 Ϯ 0.18 (0.22-2.1)</cell></row><row><cell>Ubiquitin positive</cell><cell>0.70 Ϯ 0.41 (0.66-2.51)</cell></row></table><note>SMI-31 positive1.95 Ϯ 0.41 (0.32-4.48)</note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0">March (1 of 2) 2000 NEUROLOGY 54 1037</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1">March (1 of 2) 2000 NEUROLOGY 54 1039</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_2">March (1 of 2) 2000 NEUROLOGY 54 1041</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgment</head><p>The authors thank Julie Sauer and Lois Rowe for expert technical assistance.</p></div>
			</div>


			<div type="funding">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Supported by USPHS grant NS6277 and a research grant from the Muscular Dystrophy Association.</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The crystallins: genes, proteins, and diseases</title>
		<author>
			<persName><forename type="first">J</forename><surname>Graw</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Chem</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="1331" to="1348" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Purification and characterization of a 20-kDa protein that is highly homologous to ␣B-crystallin</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Goto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Inaguma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hasegawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Morishita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Asano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">269</biblScope>
			<biblScope unit="page" from="15302" to="15309" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Cellular distribution of ␣B-crystallin in nonlenticular tissues</title>
		<author>
			<persName><forename type="first">T</forename><surname>Iwaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kume-Iwaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Goldman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Histochem Cytochem</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="31" to="39" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">␣B-Crystallin in cardiac tissue. Association with actin and desmin filaments</title>
		<author>
			<persName><forename type="first">F</forename><surname>Bennardini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wrzosek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chiesi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Res</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="288" to="294" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Chaperone activity of ␣B-crystallin suppresses tubulin aggregation through complex formation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Arai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Atomi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Struct Funct</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="539" to="544" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Mutation R120G in ␣B-crystallin, which is linked to a desmin-related myopathy, results in an irregular structure and defective chaperone-like function</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Bova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Yaron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="6137" to="6142" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">ATP-enhanced molecular chaperone function of the small heat-shock protein human ␣B-crystallin</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Muchowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Clark</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="1004" to="1009" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">␣B-Crystallin interacts with intermediate filaments in response to stress</title>
		<author>
			<persName><forename type="first">K</forename><surname>Djabali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Nechaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Landon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Portier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Sci</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="2759" to="2769" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Alpha B-crystallin in the normal human myocardium and cardiac conducting system</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">H</forename><surname>Leach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Tsang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Church</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lowe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pathol</title>
		<imprint>
			<biblScope unit="volume">173</biblScope>
			<biblScope unit="page" from="255" to="260" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Alpha B-crystallin in skeletal muscle: purification and localization</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Atomi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Strohman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nonomura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biochem (Tokyo)</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="812" to="822" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Expression of the murine alpha B-crystallin gene in lens and skeletal muscle: identification of a muscle-preferred enhancer</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Dubin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gopal-Srivastava</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Wawrousek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Piatigorsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="4340" to="4349" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Alpha B-crystallin expression in non-lenticular tissues and selective presence in ubiquinated inclusion bodies in human disease</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Mcdermott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Pike</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Spendlove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Landon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Mayer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pathol</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="page" from="61" to="68" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Van Sechel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Bajramovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mjb</forename><surname>Van Stipdonk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Persoon-Deen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Geutskens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Van Noort</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="page" from="129" to="135" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Coordinate and independent regulation of alpha-B-crystallin and hsp27 expression in response to physiological stress</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Head</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Corbin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Goldman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Physiol</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="41" to="50" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Cairns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Atkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Hanger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Anderton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Daniel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Lantos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci Lett</title>
		<imprint>
			<biblScope unit="volume">230</biblScope>
			<biblScope unit="page" from="49" to="52" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Establishing a pathological diagnosis in degenerative dementias</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lowe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain Pathol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="403" to="406" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Tau, ubiquitin, and ␣B-crystallin immunohistochemistry define the principal causes of degenerative frontotemporal dementia</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jackson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Mann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="1011" to="1015" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Neurodegeneration in the limbic and paralimbic system in progressive supranuclear palsy</title>
		<author>
			<persName><forename type="first">I</forename><surname>Higuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Iwaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tateishi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropathol Appl Neurobiol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="246" to="254" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Expression of ␣B-crystallin in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">K</forename><surname>Renkawek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Voorter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Bosman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">P</forename><surname>Van Norkum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jong</forename><forename type="middle">Ww</forename><surname>De</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol (Berl)</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="155" to="160" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Fourteen newly recognized proteins at the human neuromuscular junctions and their nonjunctional accumulation in inclusion body myositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann NY Acad Sci</title>
		<imprint>
			<biblScope unit="volume">841</biblScope>
			<biblScope unit="page" from="28" to="56" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Sporadic inclusion body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="389" to="405" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Mendell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Sahenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gales</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Paul</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1229" to="1234" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Sporadic inclusion body myositis: counts of different types of abnormal fibers</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Pruitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Showalter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="139" to="143" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title level="m" type="main">Inclusion body myositis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mikol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<editor>Myology.</editor>
		<imprint>
			<date type="published" when="1994">1994</date>
			<publisher>McGraw-Hill</publisher>
			<biblScope unit="page" from="1384" to="1398" />
			<pubPlace>New York</pubPlace>
		</imprint>
	</monogr>
	<note>2nd ed</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion body myopathies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mirabella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bilak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="774" to="786" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title level="m" type="main">Polymyositis and dermatomyositis syndromes</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">Q</forename><surname>Banker</surname></persName>
		</author>
		<editor>Myology.</editor>
		<imprint>
			<date type="published" when="1994">1994</date>
			<publisher>McGraw-Hill</publisher>
			<biblScope unit="page" from="1335" to="1383" />
			<pubPlace>New York</pubPlace>
		</imprint>
	</monogr>
	<note>2nd ed</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Myofibrillar myopathy with abnormal foci of desmin positivity. II. Immunocytochemical analysis reveals accumulation of multiple other proteins</title>
		<author>
			<persName><forename type="first">De</forename><surname>Bleecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Ertl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="563" to="577" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title level="m" type="main">The muscle biopsy</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<editor>Myology.</editor>
		<imprint>
			<date type="published" when="1994">1994</date>
			<publisher>McGraw-Hill</publisher>
			<biblScope unit="page" from="822" to="831" />
			<pubPlace>New York</pubPlace>
		</imprint>
	</monogr>
	<note>2nd ed</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Enhanced detection of Congo red positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer&apos;s disease using fluorescence technique</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="1265" to="1267" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Expression of 65-kd heat shock proteins in the inflammatory myopathies</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="821" to="823" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Increase of nitric oxide synthases and nitrotyrosine in inclusion body myositis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">NeuroReport</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="153" to="158" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Nitric oxide-induced oxidative stress in autosomal recessive and dominant inclusion body myositis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Heller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="1089" to="1097" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Sporadic inclusion body myositis and hereditary inclusion body myopathies: current concepts of diagnosis and pathogenesis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="530" to="542" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Desmin-related myopathies</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Goebel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Neurol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="426" to="429" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">A missense mutation in the ␣B-crystallin chaperone gene causes a desmin-related myopathy</title>
		<author>
			<persName><forename type="first">P</forename><surname>Vicart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Caron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Guicheney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="92" to="95" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Alpha B-crystallin in oxidative muscle fibers and its accumulation in ragged-red fibers: a comparative immunohistochemical and histochemical study in human skeletal muscle</title>
		<author>
			<persName><forename type="first">T</forename><surname>Iwaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Iwaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Goldman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol (Berl)</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="475" to="480" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Acute quadriplegic myopathy: analysis of myosin isoforms and evidence for calpain-mediated proteolysis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Showalter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="316" to="322" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Glucocorticoids regulate the expression of the stressprotein alpha B-crystallin</title>
		<author>
			<persName><forename type="first">B</forename><surname>Scheier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Foletti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stark</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Endocrinol</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="187" to="198" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Differential expression of B-crystallin and Hsp27 in skeletal muscle during continuous contractile activity. Relationship to myogenic regulatory factors</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Neufer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>Benjamin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">271</biblScope>
			<biblScope unit="page" from="24089" to="24095" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Prostaglandins stimulate the stress-induced synthesis of hsp27 and ␣B-crystallin</title>
		<author>
			<persName><forename type="first">H</forename><surname>Ito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Okamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Physiol</title>
		<imprint>
			<biblScope unit="volume">170</biblScope>
			<biblScope unit="page" from="255" to="262" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Synthesis and accumulation of alpha B-crystallin in C6 glioma cells is induced by agents that promote disassembly of microtubules</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Inaguma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Okamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Saga</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">271</biblScope>
			<biblScope unit="page" from="26989" to="26994" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Human hsp27, Drosphila hsp27, and human alpha B-crystallin expression-mediated increase in glutathione is essential for the protective activity of these proteins against TNF alphainduced cell death</title>
		<author>
			<persName><forename type="first">P</forename><surname>Mehlen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kretz-Remy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Preville</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Arrigo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EMBO J</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="2695" to="2706" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Immunolocalization of transcription factor NF-kappa B in inclusion body myositis and at normal human neuromuscular junctions</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci Lett</title>
		<imprint>
			<biblScope unit="volume">254</biblScope>
			<biblScope unit="page" from="77" to="80" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Analysis of cytokine expression in inflammatory myopathies, Duchenne dystrophy, and non-weak controls</title>
		<author>
			<persName><forename type="first">I</forename><surname>Lundberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Brengman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuroimmunol</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="9" to="16" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Conspicuous accumulation of a single-stranded DNA binding protein in skeletal muscle fibers in inclusion body myositis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Nalbantoglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Karpati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Carpenter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="page" from="874" to="882" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Purification of the stress protein alpha B-crystallin and its differentially phosphorylated forms</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Van Noort</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Veelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hopstaken</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol Methods</title>
		<imprint>
			<biblScope unit="volume">221</biblScope>
			<biblScope unit="page" from="159" to="168" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Agerelated changes in bovine alpha-crystallin and highmolecular-weight protein</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Carver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Nicholls</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Aquilina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Truscott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Eye Res</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="639" to="647" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">The influence of some posttranslational modifications on the chaperone-like activity of alpha-crystallin</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Van Boekel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Hoogakker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Harding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jong</forename><forename type="middle">Ww</forename><surname>De</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ophthalmic Res</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="32" to="38" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">T cells discriminate between differentially phosphorylated forms of alpha B-crystallin, a major central nervous system myelin antigen</title>
		<author>
			<persName><forename type="first">Mjb</forename><surname>Van Stipdonk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Willems</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Amor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Immunol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="943" to="950" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">The small heat shock protein ␣B-crystallin as key autoantigen in multiple sclerosis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Van Noort</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Van Sechel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mjb</forename><surname>Van Stipdonk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Bajramovic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Prog Brain Res</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="435" to="452" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Structure of peptides associated with MHC class I molecules</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">H</forename><surname>Engelhard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cur Opin Immunol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="13" to="23" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Alpha-crystallin can function as a molecular chaperone</title>
		<author>
			<persName><forename type="first">J</forename><surname>Horwitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="10449" to="10453" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Stress (heat shock) proteins: molecular chaperones in cardiovascular biology and disease</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>Benjamin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Mcmillan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Res</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="117" to="132" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: the mumps virus hypothesis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Nishino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Rima</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="260" to="264" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: investigation of the mumps virus hypothesis by polymerase chain reaction</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Ward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Robbins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Swanson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="23" to="28" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Absence of persistent infection with enteroviruses in muscles of patients with inflammatory myopathies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Leon-Monzon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="219" to="222" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Absence of coxsackie viruses in idiopathic inflammatory muscle disease by in situ hybridization</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Hilton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fletcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Pringle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropathol Appl Neurobiol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="238" to="242" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Leff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Love</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">339</biblScope>
			<biblScope unit="page" from="1192" to="1195" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Sporadic inclusion body myositis in an HTLV-1-positive Iranian Muslim</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Haginoya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sabetian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bajoghli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">A124</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>Abstract</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Inclusion body myositis in HIV-1 and HTLV-1 infected patients</title>
		<author>
			<persName><forename type="first">E</forename><surname>Cupler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Leon-Monzon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Semino-Mora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="1887" to="1893" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Biotechnological agents for the immunotherapy of multiple sclerosis. Principals, problems and perspectives</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="865" to="916" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
